TOP TEN perturbations for 1553634_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553634_a_at
Selected probe(set): 1553634_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553634_a_at (1553634_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):-1.8646984
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

BEZ235 study 1 (3.606 uM) / vehicle (DMSO) treated A2058 cell samples

Relative Expression (log2-ratio):1.8260956
Number of Samples:4 / 4
Experimental BEZ235 study 1 (3.606 uM)
A2058 cells treated with 3.606 uM NVP-BEZ235 for 24hours. The concentration corresponding to the IC90 of BKM120. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---
Control vehicle (DMSO) treated A2058 cell samples
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine.

juvenile psoriatic arthritis study 1 / normal PBMC sample

Relative Expression (log2-ratio):-1.7796631
Number of Samples:2 / 29
Experimental juvenile psoriatic arthritis study 1
Peripheral blood mononuclear cell (PBMC) samples from children with juvenile psoriatic arthritis. All patients were free of disease modifying antirheumatic drugs.
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children; age (mean ± SD): 10.8 ± 5.3 years.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):1.686985
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)

Relative Expression (log2-ratio):-1.6836033
Number of Samples:20 / 18
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (lesional; children)
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

atopic dermatitis study 12 (lesional; adults) / normal skin tissue (adults)

Relative Expression (log2-ratio):-1.6712351
Number of Samples:20 / 11
Experimental atopic dermatitis study 12 (lesional; adults)
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control normal skin tissue (adults)
Skin biopsy samples from healthy adults (age range 38–57 years).

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; placebo; 15d)

Relative Expression (log2-ratio):1.5739107
Number of Samples:8 / 5
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 15d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with placebo.

peptidoglycan study 1 / mock treated neonatal neutrophils

Relative Expression (log2-ratio):1.5306454
Number of Samples:3 / 3
Experimental peptidoglycan study 1
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control mock treated neonatal neutrophils
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

BEZ235 study 1 (IC90) / vehicle (DMSO) treated A2058 cell samples

Relative Expression (log2-ratio):1.5236158
Number of Samples:4 / 4
Experimental BEZ235 study 1 (IC90)
A2058 cells treated with NVP-BEZ235 for 24hours at an IC90 concentration. Concentration of IC90 was judged by reduction of pAkt levels (S473P-Akt inhibition) and the value is not clear from the article. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---
Control vehicle (DMSO) treated A2058 cell samples
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine.

glioma study 16 (astrocytoma) / normal brain tissue

Relative Expression (log2-ratio):1.5113859
Number of Samples:8 / 2
Experimental glioma study 16 (astrocytoma)
Primary astrocytoma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade III-IV).
Control normal brain tissue
Normal brain tissue sample from healthy donors.